A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes

Background: Cisplatin is an effective agent for triple-negative breast cancer (TNBC) and synergistic activity between cisplatin and capecitabine has been demonstrated by in vitro and in vivo studies. This study was designed as a prospective clinical trial to evaluate the efficacy and safety of capec...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Biol Ther
Auteurs principaux: Li, Qiao, Li, Qing, Zhang, Pin, Yuan, Peng, Wang, Jiayu, Ma, Fei, Luo, Yang, Fan, Ying, Cai, Ruigang, Xu, Binghe
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2015
Sujets:
Clinical Study
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4847806/
https://ncbi.nlm.nih.gov/pubmed/26466918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1095400
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires